NCT03690024 is a clinical trial in Hemolytic Uremic Syndrome of Childhood, sponsored by Assiut University.

Who is sponsoring NCT03690024?

NCT03690024 is sponsored by Assiut University.

What condition does NCT03690024 study?

NCT03690024 studies Hemolytic Uremic Syndrome of Childhood.

Is NCT03690024 still recruiting?

NCT03690024 is currently status unknown. Last updated 1 October 2018.

Last reviewed 2018-10-01 · How we verify

NCT03690024

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital

Status unknown Last updated 1 October 2018

What this trial tests

trial in Hemolytic Uremic Syndrome of Childhood in 50 participants. Status unknown.

Timeline

1 October 2018

Primary endpoint
1 October 2019

1 December 2019

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 October 2018
Primary completion	1 October 2019
Estimated completion	1 December 2019

Conditions studied

Hemolytic Uremic Syndrome of Childhood — all drugs for Hemolytic Uremic Syndrome of Childhood →

Sponsor

Assiut University

Who can join

Under 18, any sex, with Hemolytic Uremic Syndrome of Childhood. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diarrhea-associated hemolytic uremic syndrome (D+HUS) is defined as a prodrome of enteritis followed by thrombocytopenia (\< 150,000/mm3), microangiopathic hemolytic anemia, and signs of variable degrees of renal damage (increase in serum Cr, proteinuria, and/or hematuria) . Our aim is to detect the most reliable early predictors of poor prognosis to identify children at major risk of bad outcome who could eventually benefit from early specific treatments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03690024 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 1 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03690024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing